<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dose and schedule of primary pharmacologic therapies for heart failure with reduced ejection fraction in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dose and schedule of primary pharmacologic therapies for heart failure with reduced ejection fraction in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dose and schedule of primary pharmacologic therapies for heart failure with reduced ejection fraction in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1">Type of therapy</td> <td class="subtitle1">Role in therapy</td> <td class="subtitle1">Drug</td> <td class="subtitle1">Typical initial dose (oral)</td> <td class="subtitle1">Target dose</td> <td class="subtitle1">Minimum dose titration interval</td> </tr> <tr> <td rowspan="9">Renin-angiotensin system inhibitors/neprilysin inhibitors</td> <td>Preferred</td> <td>Sacubitril-valsartan (ARNI)</td> <td>24/26 to 49/51 mg twice daily*</td> <td>97/103 mg twice daily</td> <td rowspan="9">Double dose after 1 to 2 weeks or as tolerated<sup>¶</sup></td> </tr> <tr> <td rowspan="8">Alternatives</td> <td>Lisinopril</td> <td>2.5 to 5 mg once daily</td> <td>20 to 40 mg once daily</td> </tr> <tr> <td>Ramipril</td> <td>1.25 to 2.5 mg once daily</td> <td>10 mg once daily</td> </tr> <tr> <td>Enalapril</td> <td>2.5 mg twice daily</td> <td>10 to 20 mg twice daily</td> </tr> <tr> <td>Captopril</td> <td>6.25 mg three times daily</td> <td>50 mg three times daily</td> </tr> <tr> <td>Trandolapril</td> <td>1 mg once daily</td> <td>4 mg once daily</td> </tr> <tr> <td>Losartan</td> <td>25 to 50 mg once daily</td> <td>150 mg once daily</td> </tr> <tr> <td>Candesartan</td> <td>4 to 8 mg once daily</td> <td>32 mg once daily</td> </tr> <tr> <td>Valsartan</td> <td>20 to 40 mg twice daily</td> <td>160 mg twice daily</td> </tr> <tr> <td rowspan="5">Beta blockers</td> <td rowspan="5">Preferred</td> <td rowspan="2">Carvedilol</td> <td rowspan="2">3.125 mg twice daily</td> <td>≤85 kg: 25 mg twice daily</td> <td rowspan="5">Double every 2 weeks<sup>¶</sup></td> </tr> <tr> <td>&gt;85 kg: 50 mg twice daily</td> </tr> <tr> <td>Carvedilol CR</td> <td>10 mg once daily</td> <td>80 mg once daily</td> </tr> <tr> <td>Metoprolol succinate CR</td> <td>12.5 to 25 mg once daily</td> <td>200 mg once daily</td> </tr> <tr> <td>Bisoprolol</td> <td>1.25 mg once daily<sup>Δ</sup></td> <td>10 mg once daily</td> </tr> <tr> <td rowspan="2">Mineralocorticoid receptor antagonists</td> <td rowspan="2">Preferred</td> <td>Spironolactone</td> <td>12.5 to 25 mg once daily</td> <td>25 to 50 mg once daily or in two divided doses</td> <td rowspan="2">Double every 4 weeks<sup>¶</sup></td> </tr> <tr> <td>Eplerenone</td> <td>25 mg once daily</td> <td>50 mg once daily</td> </tr> <tr> <td rowspan="3">SGLT2 inhibitors</td> <td rowspan="2">Preferred</td> <td>Dapagliflozin</td> <td colspan="2">10 mg once daily</td> <td rowspan="3">Fixed dose</td> </tr> <tr> <td>Empagliflozin</td> <td colspan="2">10 mg once daily</td> </tr> <tr> <td>Alternative</td> <td>Canagliflozin</td> <td colspan="2">100 mg once daily</td> </tr> </tbody></table></div><div class="graphic_lgnd">Only 1 drug from each type of therapy should be used. The drug doses and intervals for dose changes are for patients who do not require dose adjustments due to factors such as comorbid illnesses, kidney or hepatic dysfunction, drug interactions, or other reasons. Consult appropriate UpToDate content, Lexicomp drug monographs, or other resources to determine the appropriate dosing for a given patient. The <a href="https://www.uptodate.com/drug-interactions?source=responsive_home" target="_blank">drug interactions program</a> included within UpToDate may be used to confirm there are no clinically significant drug interactions. Monitoring of therapy is discussed in UpToDate content on treatment of heart failure with reduced ejection fraction.</div><div class="graphic_footnotes"><p>CR: controlled release;
SGLT2: sodium-glucose co-transporter 2;
ARNI: angiotensin receptor-neprilysin inhibitor;
ACE: angiotensin converting enzyme;
ARB: angiotensin II receptor blocker;
HFrEF: heart failure with reduced ejection fraction.</p>
<p>* Selection of initial dose of ARNI is dependent upon whether patient has been treated previously with a moderate to high dose of an ACE inhibitor or ARB; to reduce risk of toxicity, a 36-hour washout period is required if switching from ACE inhibitor to ARNI. Refer to Lexicomp monograph.</p>
<p>¶ Dose increases may be performed more rapidly in a management program or with other forms of monitoring for complications. The requirements for monitoring are described in UpToDate content on
pharmacologic therapy for HFrEF.</p>
Δ In the United States, the lowest available bisoprolol tablet strength is 5 mg. A 1.25 mg dose requires splitting a round tablet into quarters, which may be difficult and inaccurate.</div><div class="graphic_reference">Data from: Lexicomp Online. Copyright © 1978-2024 Lexicomp, Inc. All Rights Reserved.</div><div id="graphicVersion">Graphic 140887 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
